Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients.
Sharpe J, Schnell P, Knopp M, Binzel K, Magyer M, Cherian M, Gatti-Mays M, Pariser A, Wesolowski R, Sardesai S, VanDeusen J, Stover D, Ramaswamy B, Williams N, DeVries A, Shinde N, Orchard T, Lustberg M. Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients. Journal Of Clinical Oncology 2021, 39: e12528-e12528. DOI: 10.1200/jco.2021.39.15_suppl.e12528.Peer-Reviewed Original ResearchPET/CT imagingPET/CTCytokine levelsMicroglial activationCT imagingF-fluorodeoxyglucoseDouble-blinded randomized placebo-controlled trialBlinded randomized placebo-controlled trialChemotherapy-induced cognitive changesRandomized placebo-controlled trialCognitive functionPlacebo-controlled trialInflammatory cytokine levelsBreast cancer patientsCognitive changesCT brain imagingAC therapyDaily minocyclinePotent mitigatorNeoadjuvant chemotherapyPlacebo groupInflammatory markersInflammatory changesMedian ageMinocycline group